| scholarly article | Q13442814 |
| P2093 | author name string | Raghavendra M Rao | |
| Prashanth G Ramachandra | |||
| Veerendra Bhadrasetty | |||
| P S Sridhar | |||
| Shivakumar S Swamy | |||
| Basavalingaiah S Ajaikumar | |||
| Hemantha M Kumara | |||
| Indiresh Desai | |||
| Krishnappa Rajkumar | |||
| Kumaraswamy G Kallur | |||
| Nagaraj Madhusudhan | |||
| Raghunath S Krishnappa | |||
| S D Santhosh | |||
| Shekhar Gowda Patil | |||
| P2860 | cites work | Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer | Q28236013 |
| Constitutive and antibody-induced internalization of prostate-specific membrane antigen. | Q32015731 | ||
| Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. | Q33302131 | ||
| National Comprehensive Cancer Network guidelines for the management of prostate cancer | Q34187291 | ||
| Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. | Q34228828 | ||
| Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer | Q35645376 | ||
| Technical considerations when obtaining and interpreting prostatic biopsies from men with suspicion of early prostate cancer: part I. | Q36118574 | ||
| Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. | Q36165709 | ||
| Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer | Q37091554 | ||
| Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer | Q37350456 | ||
| Current approaches, challenges and future directions for monitoring treatment response in prostate cancer. | Q37435181 | ||
| PET imaging in prostate cancer: focus on prostate-specific membrane antigen | Q38099369 | ||
| Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction | Q38406281 | ||
| 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging | Q39389586 | ||
| Evaluation of androgen-induced effects on the uptake of [18F]FDG, [11C]choline and [11C]acetate in an androgen-sensitive and androgen-independent prostate cancer xenograft model | Q40275645 | ||
| Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization | Q41104629 | ||
| A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer | Q41600550 | ||
| Sensitivity and specificity of PET/CT regarding the detection of lymph node metastases in prostate cancer recurrence | Q41827640 | ||
| Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases | Q42456087 | ||
| Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy | Q43276156 | ||
| Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer | Q44192340 | ||
| Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy | Q45098501 | ||
| First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer | Q45868903 | ||
| Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence. | Q46124196 | ||
| Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer | Q46642656 | ||
| Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? | Q46825545 | ||
| Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. | Q52426889 | ||
| PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. | Q53131398 | ||
| [18F]choline positron emission tomography in prostate cancer patients with biochemical recurrence after radical prostatectomy: influence of antiandrogen therapy - a preliminary study. | Q53156991 | ||
| 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. | Q53488259 | ||
| [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. | Q53527477 | ||
| Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer. | Q54683192 | ||
| Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells | Q73260063 | ||
| Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases | Q77378855 | ||
| Time to achieve a prostate specific antigen nadir of 0.2 ng./ml. after simultaneous irradiation for prostate cancer | Q78544236 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 110-117 | |
| P577 | publication date | 2017-04-01 | |
| P1433 | published in | Indian Journal of Nuclear Medicine | Q15816793 |
| P1476 | title | Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer | |
| P478 | volume | 32 |
| Q57109403 | Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer |
| Q57107850 | Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer |
| Q89823517 | Imaging for Metastasis in Prostate Cancer: A Review of the Literature |
| Q93048458 | Liquid Biopsy in Oligometastatic Prostate Cancer-A Biologist's Point of View |
| Q58593270 | Nonspecific Uptake of Ga-Prostate-Specific Membrane Antigen in Diseases other than Prostate Malignancy on Positron Emission Tomography/Computed Tomography Imaging: A Pictorial Assay and Review of Literature |
Search more.